Want to see TCRX full AI Analyst Report?
TCRX Stock Chart & Stats
$0.79
-$0.05(-6.19%)
At close: 4:00 PM EDT
$0.79
-$0.05(-6.19%)
Day’s Range― - ―
52-Week Range$0.73 - $2.57
Previous CloseN/A
Volume1.06M
Average Volume (3M)476.93K
Market Cap
$48.56M
Enterprise Value$95.69
Total Cash (Recent Filing)$128.06M
Total Debt (Recent Filing)$92.54M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Aug 19, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding61,074,230
10 Day Avg. Volume455,904
30 Day Avg. Volume476,927
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.05
Price to Sales (P/S)12.58
P/FCF Ratio-0.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside659.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.03
Revenue Forecast (FY)$7.86M
Bulls Say, Bears Say
Bulls Say
Manufacturing & Clinical ReadinessA ~90% manufacturing success with a commercial-ready process and movement toward a pivotal Phase 3 materially reduces CMC and scale-up risk. This operational readiness is a durable advantage: it raises the probability of completing late-stage development, attracts partners, and eases future commercialization logistics.
High Gross MarginSustained gross margins near 92% indicate favorable unit economics for discovery/licensing and biologics manufacturing activities. Durably positive, strong gross margins can fund a larger share of R&D or improve royalty economics upon commercialization, supporting long-term viability once products reach market.
Manageable LeverageLeverage around 0.62 with positive equity gives the company a measure of financial flexibility relative to highly levered peers. This structural position supports the ability to access debt or partnership funding to bridge development milestones, moderating immediate solvency risk while programs advance.
Bears Say
High Cash BurnConsistently large negative operating and free cash flows indicate the company is consuming substantial cash to fund development. This durable pressure forces ongoing reliance on external financing, elevates dilution risk, and can constrain long-term execution if capital access tightens or trial timelines extend.
Persistent Losses And Weak RevenueVery large trailing losses paired with modest, declining revenue show the business is not yet self-sustaining. Structurally negative: absent successful clinical readouts or partnering, the cost base will remain far above revenue, prolonging financing needs and increasing strategic pressure on programs and management choices.
Expanded Dilution CapacityDoubling authorized shares materially increases the company’s capacity to issue equity. This structural change raises the probability and potential magnitude of future dilution, weakening existing shareholder ownership and making equity financing a more likely tool to cover persistent burn and fund late-stage development.
TScan Therapeutics News
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $0.73 and its highest was $2.57 in the past 12 months.
What is TScan Therapeutics’s market cap?
TScan Therapeutics’s market cap is $48.56M.
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 17 days.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on May 06, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.202 by -$0.018.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 61,074,230 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.202. Following the earnings report the stock price went up 3.306%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Currently, no hedge funds are holding shares in TCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TScan Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (659.49% Upside)
$6.00 (659.49% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.1%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.29%
Trailing 12-Months
Company Description
TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TCRX Stock 12 Month Forecast
Average Price Target
$6.00
▲(659.49% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
ALX Oncology Holdings
―
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
Ownership Overview
17.47% Insiders
5.44% Mutual Funds
0.02% Other Institutional Investors
73.23% Public Companies and
Individual Investors